Related content

Compliance with osteoporosis drug therapy and risk of fracture

By Weycker D.   Macarios D.   Edelsberg J.   Oster G.  

Osteoporosis International, Vol. 18, Iss. 3, 2007-03 ,pp. : 271-277

Springer Publishing Company

Access to resources Recommend Favorite

Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis

By Penning-van Beest Fernie J. A.   Erkens Joëlle A.   Olson M.   Herings Ron M. C.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1337-1344

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis?

By Lewiecki E. Michael  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1493-1497

Informa Healthcare

Access to resources Recommend Favorite

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

By Cramer Joyce A.   Amonkar Mayur M.   Hebborn Ansgar   Altman Roy  

Current Medical Research and Opinion, Vol. 21, Iss. 9, 2005-09 ,pp. : 1453-1460

Informa Healthcare

Access to resources Recommend Favorite

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

By Ringe J. D.   Christodoulakos G. E.   Mellström D.   Petto H.   Nickelsen T.   Marín F.   Pavo I.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2677-2687

Informa Healthcare

Access to resources Recommend Favorite